To the best of our knowledge, no study has analyzed the prognostic impact of PSA kinetics during ADT on PCSS in patients stratified according to their prior history of local tumor treatment, and who later received various novel approved agents targeting castration-resistant PCa (CRPC), including abiraterone, enzalutamide, 233radium, and cabazitaxel. This evidence concerns the gene KLK3 and neoplasm.